The Federal Trade Commission said Friday that it is suing three drug middlemen, accusing them of inflating insulin prices.

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...

The Federal Trade Commission Friday announced it was suing the country's three biggest pharmacy benefit managers, claiming ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of ...

FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...